Statin drugs like Lipitor may lead to systemic imbalances throughout the body via their antibacterial effect, much in the same way as antibiotics. Antibiotics have already been implicated in obesity, diabetes, life-Threatening colitis, asthma, allergies, and cancers due to their effect on the intestinal flora. Statins have many "side-effects" and some of those may be due to this antibacterial effect - http://www.ann-clinmicrob.com/content/11/1/13/abstract
Antibacterial activity of statins: a comparative study of Atorvastatin, Simvastatin, and Rosuvastatin
Statins have several effects beyond their well-known antihyperlipidemic activity, which include immunomodulatory, antioxidative and anticoagulant effects. In this study, we have tested the possible antimicrobial activity of statins against a range of standard bacterial strains and bacterial clinical isolates.
Minimum inhibitory concentrations (MIC) values were evaluated and compared among three members of the statins drug (atorvastatin, simvastatin, and rosuvastatin).
It was revealed that statins are able to induce variable degrees of antibacterial activity with atorvastatin, and simvastatin being the more potent than rosuvastatin. Methicillin-sensitive staphylococcus aureus (MSSA), methicillin-resistant staphylococcus aureus (MRSA), vancomycin-susceptible enterococci (VSE), vancomycin-resistant enterococcus (VRE), acinetobacter baumannii, staphylococcus epidermidis, and enterobacter aerogenes, were more sensitive to both atorvastatin, and simvastatin compared to rosuvastatin. On the other hand, escherichia coli, proteus mirabilis, and enterobacter cloacae were more sensitive to atorvastatin compared to both simvastatin and rosuvastatin. Furthermore, most clinical isolates were less sensitive to statins compared to their corresponding standard strains.
Our findings might raise the possibility of a potentially important antibacterial class effect for statins especially, atorvastatin and simvastatin.